Researchers at the Scripps Research Institute have developed a blood test that detects Alzheimer's disease by analyzing how proteins fold rather than measuring their quantity. The test, published in Nature Aging, identified structural changes in three key plasma proteins — C1QA, Clusterin, and Apolipoprotein B — that distinguish healthy individuals from those with mild cognitive impairment or Alzheimer's with up to 93% accuracy.

Senior author John Yates and his team analyzed blood samples from 520 participants across NIA-funded research centers in Kansas and California. Using mass spectrometry and machine learning, they found that as Alzheimer's progresses, certain blood proteins become less structurally "open." The method also revealed biological differences between male and female patients not captured by existing biomarkers.

NIA director Richard Hodes called the work "a fundamentally new, blood-based approach to detecting and staging Alzheimer's disease." Unlike current tests that measure protein levels, this structural approach could enable earlier diagnosis and more targeted clinical trials.